Skip to search formSkip to main contentSkip to account menu

AN2690

Known as: AN 2690, AN-2690 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
2-Formylphenylboronic acids display many interesting features, not only from synthetic but also from an application as well as… 
2018
2018
Today, medicinal chemistry is still clearly dominated by organic chemistry, and most of the marketed drugs are purely organic… 
2016
2016
Benzoxaboroles are a family of organoboron molecules, which have been finding over the past few years an increasing number of… 
2011
2011
In the crystal structure of the title compound, C7H6BFO2, a broad-spectrum antifungal drug (AN2690), the planar [maximum… 
2010
2010
Some aaRSs (aminoacyl-tRNA synthetases) develop editing mechanisms to correct mis-charged tRNA. The CP1 (connective peptide 1… 
Review
2007
Review
2007
Schering-Plough Corp, under license from Anacor Pharmaceuticals Inc, is developing AN-2690, an antifungal agent with activity… 
2007
2007
References 1. rock Fl et al (2007) an antifungal agent inhibits an aminoacyl-trNa synthetase by trapping trNa in the editing site… 
2007
2007
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the…